{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"45.6","value":"21.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants in the analysis population who experienced a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) and was assessed using RECIST 1.1 based on BICR evaluation. The percentage of participants who were from the Asia Pacific region and experienced a CR or PR in Cohort D was presented for the first course of pembrolizumab treatment per protocol.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who were from the Asia Pacific region received pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"OG000","title":"Cohort D: Gastric Cancer AP Participants"}],"paramType":"NUMBER","populationDescription":"The population consisted of all Cohort D participants from AP region who received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression (Up to ~ 35 months) - through FA cutoff date 26 Apr 2016","title":"Overall RECIST 1.1 Response Rate Based on BICR Review, Cohort D Asia-Pacific (AP) Participants","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}